contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


realheart-presents-successful-results-from-a-preclinical-implantation-using-its-total-artificial-heart

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Scandinavian Real Heart operates in medical technology. Today, the company's main focus is on research and development of heart pumps used among patients with severe heart conditions who are in the queue for transplant. The idea behind the heart pump is to use the product as a transitional solution before a final heart transplant is performed. The company is based in Västerås.

Scandinavian Real Heart

Västerås, Sweden, January 30, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has successfully completed a 7-day animal study with its total artificial heart Realheart...

<div class="mfn-preamble"><p><strong>Västerås, Sweden, January 30, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has successfully completed a 7-day animal study with its total artificial heart Realheart® TAH. The results show that the device provided adequate cardiac function, automatically adapted to rest and movement and maintained good blood biochemistry.</strong></p></div><div class="mfn-body"><p>“We are very pleased to share this positive update. Results from the implantation test show that Realheart® TAH achieved the targeted cardiac output, resulting in adequate perfusion of the body with low mechanical stress and damage to red blood cells” says Ina Laura Perkins, CEO of Realheart.</p><p>Throughout the study the device functioned as intended. At one week the study was terminated as there had been some signs of bleeding which is a common complication of large cardiac surgery.</p><p>“A 7-day chronic implantation is a meaningful milestone for our development as this duration affords the assessment of the device performance in an animal that is awake and ambulatory and under various cardiac loads and allows for the elimination of many post-surgical effects”, says CEO Ina Laura Perkins.</p><p>The company is currently conducting a preclinical program to evaluate the safety and function of Realheart® TAH prior to conducting clinical studies in heart failure patients. The results from this test will guide further preclinical testing of Realheart® TAH and serve as an integral part of the data set used in dialogue with regulatory agencies.</p></div><div class="mfn-footer mfn-contacts mfn-ddde9c982a0b"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Ina Laura Perkins, CEO<br>Phone: +46 (0) 70 406 49 21&nbsp;<br>E-mail: <a rel="noopener" href="mailto:inalaura.perkins@realheart.se">inalaura.perkins@realheart.se</a><br>Certified Adviser: Svensk Kapitalmarknadsgranskning AB, <a rel="noopener" href="http://www.skmg.se">www.skmg.se</a></p></div><div class="mfn-footer mfn-about mfn-0285b54ad9f5"><p><strong class="mfn-heading-1">About Us</strong><br>Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit <a rel="noopener" href="http://www.realheart.se">www.realheart.se</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Scandinavian Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-30 13:40 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/b44d233b-3653-4112-8e50-5cf02e937b3c/realheart-presents-successful-results-from-a-preclinical-implantation-using-its-total-artificial-heart.pdf" class="mfn-generated mfn-primary">Realheart Presents Successful Results From a Preclinical Implantation Using Its Total Artificial Heart</a></p></div>

Realheart Presents Successful Results From a Preclinical Implantation Using Its Total Artificial Heart